

Long-time pharma rivals unite to fight a common enemy: COVID-19

In the age of Covid-19, old adversaries are uniting around a common enemy: the new coronavirus. Their nascent partnership is now visible in everything from [trials to research to manufacturing](#). Glaxo and eight other pharmaceutical firms even took the rare step of [issuing a joint pledge](#) last month to seek regulatory approvals for their vaccines only after proving their safety and effectiveness in large, final-stage clinical trials.

The most common area of cooperation thus far is manufacturing. Some longtime rivals are striking deals to stretch their capacity to meet anticipated demand. [Roche Holding AG is helping manufacture an antiviral drug in development by rival Regeneron](#). [Amgen](#) Inc. will help make [Eli Lilly](#) & Co.'s antiviral drugs if the treatments are authorized by regulators. [Pfizer](#) has dedicated manufacturing capacity to turning out doses of remdesivir, an antiviral made by rival [Gilead Sciences](#) Inc.

The camaraderie also extends to the traditionally cutthroat realm of research. [Regeneron Pharmaceuticals](#) Inc. scientists contributed to research on a vaccine in development by [BioNTech SE](#) and Pfizer Inc., and were [co-authors on a paper this summer detailing the results](#).

Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other 'disruptive' innovations. Subscribe to our newsletter.

[SIGN UP](#)

"When you're facing a public-health crisis there is no team with a blue T-shirt and a team with an orange T-shirt. Very quickly, there was only one team," [Sanofi's Thomas] Triomphe said.

[Read the original post](#)